Trigone Pharma (“Trigone”), a pharmaceutical company pioneering prolonged intravesical treatment combined with targeted therapies for the treatment of bladder cancer, today announced a collaboration with 4C Biomed, to develop an innovative treatment for bladder cancer. The collaboration will focus on local administration of 4C Biomed’s anti 4CB-1 as an innovative treatment for high-grade non-muscle invasive bladder cancer.
Trigone Pharma Ltd. a leader in the field of urological diseases, today announced the initiation of a Phase 2 study of TRG-100 in patients with interstitial cystitis/ bladder pain syndrome (IC/BPS). The study will enroll patients who have recurred or progressed following standard therapy or have not responded to prior standard therapy.